STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBIO
  4. [Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

BBIO Form 4: BridgeBio director discloses November 2025 share sales

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) director insider transactions were reported on a Form 4. A reporting person serving as a director disclosed open-market sales of BridgeBio common stock on 11/17/2025 and 11/18/2025 at weighted average prices ranging from about $64.58 to $67.20 per share, with specific weighted averages of $66.6263, $67.056, $65.2315, and $66.049 for the reported trades.

Following these transactions, the director beneficially owned 17,887 shares of common stock directly and 50,583 shares indirectly through joint tenancy with Nancy N. Lo. The price ranges for each trade are available, and the reporting person has undertaken to provide detailed breakdowns of the individual sale prices within each range upon request.

Positive

  • None.

Negative

  • None.
Insider Lo Andrew
Role Director
Sold 95,599 shs ($6.32M)
Type Security Shares Price Value
Sale Common Stock 24,007 $65.2315 $1.57M
Sale Common Stock 30,993 $66.049 $2.05M
Sale Common Stock 36,801 $66.6263 $2.45M
Sale Common Stock 3,798 $67.056 $255K
Holdings After Transaction: Common Stock — 81,576 shares (Indirect, By Andrew W. Lo and Nancy N. Lo JTWROS); Common Stock — 17,887 shares (Direct)
Footnotes (1)
  1. Represents the weighted average sale price of the shares sold from $65.975 to $66.97 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $66.975 to $67.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $64.58 to $65.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $65.58 to $66.52 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lo Andrew
(Last) (First) (Middle)
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR., SUITE 250
(Street)
PALO ALTO CA 94304
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/17/2025 S 36,801 D $66.6263(1) 17,887 D
Common Stock 11/17/2025 S 3,798 D $67.056(2) 14,089 D
Common Stock 11/18/2025 S 24,007 D $65.2315(3) 81,576 I By Andrew W. Lo and Nancy N. Lo JTWROS
Common Stock 11/18/2025 S 30,993 D $66.049(4) 50,583 I By Andrew W. Lo and Nancy N. Lo JTWROS
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the weighted average sale price of the shares sold from $65.975 to $66.97 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
2. Represents the weighted average sale price of the shares sold from $66.975 to $67.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
3. Represents the weighted average sale price of the shares sold from $64.58 to $65.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
4. Represents the weighted average sale price of the shares sold from $65.58 to $66.52 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Will Solis, Attorney-in-Fact 11/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What type of SEC filing did BridgeBio Pharma (BBIO) report here?

This is a Form 4 filing reporting changes in beneficial ownership of BridgeBio Pharma, Inc. common stock by a company director.

Who is the reporting person in the BridgeBio (BBIO) Form 4 and what is their role?

The reporting person is a director of BridgeBio Pharma, Inc., identified in the indirect ownership entries as Andrew W. Lo, who reports both direct and joint ownership of shares.

When did the reported BridgeBio (BBIO) stock transactions occur?

The reported transactions in BridgeBio common stock took place on 11/17/2025 and 11/18/2025.

What prices were received for the BridgeBio (BBIO) shares sold in this Form 4?

The sales were reported at weighted average sale prices of $66.6263, $67.056, $65.2315, and $66.049 per share, each representing trades within specified ranges from $64.58 to $67.20.

How many BridgeBio (BBIO) shares does the director own after these transactions?

After the reported transactions, the director beneficially owns 17,887 BridgeBio common shares directly and 50,583 shares indirectly as joint tenants with Nancy N. Lo.

Are the detailed individual sale prices for the BridgeBio (BBIO) trades available?

Yes. The Form 4 states that the reporting person will provide full information on the number of shares sold at each separate price within the reported ranges upon request by the Commission staff, the issuer, or an issuer security holder.

Does this BridgeBio (BBIO) Form 4 report any derivative securities?

The Form 4 includes a table for derivative securities, but no derivative security acquisitions or dispositions are reported in that table in the provided content.